Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Marth

Showing results (171-180 of 237) with videos related to

Pageof 24
Sort By:
European Journal of Human Genetics : EJHG|May 28, 2015
High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testingLaura Pölsler, Heidi Fiegl, Katharina Wimmer, et al.
Archives of Gynecology and Obstetrics|October 16, 2014
Surgical and systemic management of endometrial cancer: an international surveyChristina Fotopoulou, Robert Kraetschell, Sean Dowdy, et al.
Frontiers in Oncology|September 26, 2019
Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 ConsortiumIsabelle Ray-Coquard, Ioana Braicu, Regina Berger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivoNicole Concin, Gerda Hofstetter, Astrid Berger, et al.
Wiener Medizinische Wochenschrift (1946)|October 17, 2015
Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statementEdgar Petru, Christian F Singer, Stephan Polterauer, et al.
Future Oncology (London, England)|September 6, 2022
EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)Panagiotis A Konstantinopoulos, Antonio Gonzalez-Martin, Felipe Melo Cruz, et al.
Gynecologic Oncology|January 16, 2022
Dubious effects of methadone as an "anticancer" drug on ovarian cancer cell-lines and patient-derived tumor-spheroidsHeidelinde Fiegl, Judith Hagenbuchner, Christiana Kyvelidou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
Genomic index of sensitivity to endocrine therapy for breast cancerW Fraser Symmans, Christos Hatzis, Christos Sotiriou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trialGeorg Pfeiler, Robert Königsberg, Christian Fesl, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2023
Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients - An international pooled analysis of three ESGO accredited centresRichard Schwameis, Francesco Fanfani, Christoph Ebner, et al.
Pageof 24

Showing results (171-180 of 237) with videos related to

Sort By:
Pageof 24
European Journal of Human Genetics : EJHG|May 28, 2015
High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testingLaura Pölsler, Heidi Fiegl, Katharina Wimmer, et al.
Archives of Gynecology and Obstetrics|October 16, 2014
Surgical and systemic management of endometrial cancer: an international surveyChristina Fotopoulou, Robert Kraetschell, Sean Dowdy, et al.
Frontiers in Oncology|September 26, 2019
Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 ConsortiumIsabelle Ray-Coquard, Ioana Braicu, Regina Berger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivoNicole Concin, Gerda Hofstetter, Astrid Berger, et al.
Wiener Medizinische Wochenschrift (1946)|October 17, 2015
Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statementEdgar Petru, Christian F Singer, Stephan Polterauer, et al.
Future Oncology (London, England)|September 6, 2022
EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)Panagiotis A Konstantinopoulos, Antonio Gonzalez-Martin, Felipe Melo Cruz, et al.
Gynecologic Oncology|January 16, 2022
Dubious effects of methadone as an "anticancer" drug on ovarian cancer cell-lines and patient-derived tumor-spheroidsHeidelinde Fiegl, Judith Hagenbuchner, Christiana Kyvelidou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
Genomic index of sensitivity to endocrine therapy for breast cancerW Fraser Symmans, Christos Hatzis, Christos Sotiriou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trialGeorg Pfeiler, Robert Königsberg, Christian Fesl, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2023
Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients - An international pooled analysis of three ESGO accredited centresRichard Schwameis, Francesco Fanfani, Christoph Ebner, et al.
Pageof 24